Study of lutetium-177-PSMA-617 for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of prostate cancer that has spread and is no longer responding to hormone therapy.
- Your doctor has already decided that this treatment is right for you.
- You are 18 years or older.
- You agree to take part and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This study tracks the experiences of men with metastatic prostate cancer who have received lutetium PSMA therapy (also known as Pluvicto). It aims to learn more about how this treatment works in real-world settings by collecting health information over time.
This study follows men with advanced prostate cancer who are receiving a new radioactive treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how well the treatment works in everyday practice, and to gather information on safety and effectiveness.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.